Cancer Research Cell Death Mechanisms and Cancer Therapy  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gu, J.
Right arrow Articles by Yuan, Z.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gu, J.
Right arrow Articles by Yuan, Z.-M.
[Cancer Research 61, 1741-1746, February 15, 2001]
© 2001 American Association for Cancer Research


Tumor Biology

Mechanism of Functional Inactivation of a Li-Fraumeni Syndrome p53 That Has a Mutation Outside of the DNA-binding Domain1

Jijie Gu, Hidehiko Kawai, Dmitri Wiederschain and Zhi-Min Yuan2

Department of Cancer Cell Biology, Harvard School of Public Health, Boston, Massachusetts 02115 [J. G., H. K., D. W., Z-M. Y.], and The Program in Biological Sciences in Public Health, Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts 02138 [D. W., Z-M. Y.]

The majority of p53 mutations are located in the DNA-binding domain of the protein. However, recently a family suffering from Li-Fraumeni syndrome (LFS) has been discovered, some of whom harbor a p53 mutation in exon 4, outside of the core domain. How this mutation affects p53 function and subsequently leads to malignant transformation is not yet clear. Interestingly, the p53 mutation found in this LFS family is localized to the p53 region that we have recently identified as necessary for Mdm2-mediated p53 degradation. We therefore endeavored to study further the LFS-associated p53 mutation at the molecular level by creating an equivalent lesion in a p53 expression construct and functionally characterizing it. Here we demonstrate that a mutation in this region is associated not only with resistance of the mutant p53 to Mdm2-mediated degradation, but also with an impaired response of mutant protein to DNA damage. In addition, the p53(LFS) mutant was found to be defective in its transactivation function, which correlated with its inability to suppress cell growth and to induce apoptosis. The molecular basis for p53(LFS) functional impairment appears to be its predominantly cytoplasmic localization caused by faulty nuclear import mechanism, which, at least in part, resulted from the mutant’s decreased affinity to importin.




This article has been cited by other articles:


Home page
Toxicol PatholHome page
S. Elmore
Apoptosis: A Review of Programmed Cell Death
Toxicol Pathol, June 1, 2007; 35(4): 495 - 516.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. M. Chan and R. Y.C. Poon
The p53 Isoform {Delta}p53 Lacks Intrinsic Transcriptional Activity and Reveals the Critical Role of Nuclear Import in Dominant-Negative Activity
Cancer Res., March 1, 2007; 67(5): 1959 - 1969.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
W. M. Chan, W. Y. Siu, A. Lau, and R. Y. C. Poon
How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer?
Mol. Cell. Biol., April 15, 2004; 24(8): 3536 - 3551.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. C. Burton, K. R. Lamborn, P. Forsyth, J. Scott, J. O'Campo, J. Uyehara-Lock, M. Prados, M. Berger, S. Passe, J. Uhm, et al.
Aberrant p53, mdm2, and Proliferation Differ in Glioblastomas from Long-Term Compared with Typical Survivors1
Clin. Cancer Res., January 1, 2002; 8(1): 180 - 187.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Li, W. Zhang, G. Chan, A. Jancso-Radek, S. Liu, and M. A. Weiss
Human Sex Reversal Due to Impaired Nuclear Localization of SRY. A CLINICAL CORRELATION
J. Biol. Chem., November 30, 2001; 276(49): 46480 - 46484.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.